White Pine Capital LLC increased its position in Codexis, Inc. (NASDAQ:CDXS – Free Report) by 13.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 249,106 shares of the biotechnology company’s stock after purchasing an additional 29,366 shares during the quarter. White Pine Capital LLC […]
White Pine Capital LLC raised its holdings in shares of Codexis, Inc. (NASDAQ:CDXS – Free Report) by 13.4% during the first quarter, according to its most recent filing with the SEC. The firm owned 249,106 shares of the biotechnology company’s stock after purchasing an additional 29,366 shares during the period. White Pine Capital LLC’s holdings […]
Codexis (NASDAQ:CDXS – Get Free Report) was downgraded by stock analysts at TD Cowen from an “outperform” rating to a “market perform” rating in a report issued on Monday, Marketbeat reports. They currently have a $4.00 price objective on the biotechnology company’s stock, down from their prior price objective of $21.00. TD Cowen’s price objective […]
Codexis (NASDAQ:CDXS – Get Free Report) and LanzaTech Global (NASDAQ:LNZA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends. Insider & Institutional Ownership 88.0% of Codexis shares […]
Codexis (NASDAQ:CDXS – Get Free Report) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04, Briefing.com reports. Codexis had a negative net margin of 41.17% and a negative return on equity of 32.75%. The company had revenue of […]